DDInter1008 DDInter927
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Ketoconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A4
Ketoconazole {u} (Compound) upregulates {v} (Gene) FDFT1
Ketoconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A5 Inhibitors
Ketoconazole {u} (Compound) downregulates {v} (Gene) PPP2R3C
Ketoconazole {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Ketoconazole {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) CYP51A1
Ketoconazole (Compound) resembles Itraconazole (Compound)
Ketoconazole (Compound) resembles Posaconazole (Compound)
Ketoconazole (Compound) binds CYP3A4 (Gene)
Ketoconazole (Compound) upregulates FDFT1 (Gene)
Ketoconazole (Compound) is included by Cytochrome P450 3A5 Inhibitors (Pharmacologic Class)
Ketoconazole (Compound) downregulates PPP2R3C (Gene)
Ketoconazole (Compound) causes Hypersensitivity (Side Effect)
Ketoconazole (Compound) binds CYP51A1 (Gene) and Ketoconazole (Compound) upregulates CYP51A1 (Gene)